LBPO.CL04 · 临床研究 · Late-Breaking
Impact of severe liver metastases on clinical response to immunotherapy in solid tumors
作者与单位
摘要 Abstract
Background: The presence of liver metastases negatively influences immunotherapy response across solid tumors by promoting an immunosuppressive microenvironment. However, it remains unclear whether a specific threshold of liver metastases, defined by lesion size and number, is associated with progressively worse response to immunotherapy-based regimens.
Methods: We retrospectively analyzed clinical and radiologic data from 594 patients with advanced solid tumors treated on immunotherapy-based clinical trials at the University of Texas MD Anderson Cancer Center between 3/2016 and 2/2022 (IRB-approved protocol PA15-0315). Baseline imaging categorized liver metastases as 1) absent; 2) mild (<5 lesions, all <3 cm); 3) moderate (<5 lesions with ≥1 lesion ≥3 cm); or 4) severe (≥5 lesions of any size). Tumor response was assessed by RECIST v1.1. Responders were defined as complete response, partial response, or stable disease (SD) lasting ≥6 months; non-responders included SD <6 months, progressive disease, or clinical progression. Odds ratios (ORs) and 95% confidence intervals (CI) for response were estimated using logistic regression.
Results: Of the 594 patients, 52% were female, 79% were white, 90% had an ECOG performance status of 1. The most common tumor types were gastrointestinal (18%) and gynecologic (14%) malignancies. A total of 537 were evaluable for response. Liver metastases were present in 213 (mild n=40, moderate n=34, severe n=139) and absent in 324 patients. The presence of liver metastases was significantly associated with lower response rates (p<0.001). Patients with severe liver metastases had lower odds of response compared to those with mild/moderate liver metastases, though the difference did not reach statistical significance (OR 0.69, 95% CI 0.30-1.58; p=0.39). The odds of response were significantly lower in patients with mild/moderate liver metastases than in patients without liver metastases (OR 0.46, 95% CI 0.23-0.90; p=0.024). Severe liver metastasis was associated with significantly lower odds of response compared to none or mild/moderate disease (OR 0.36, 95% CI 0.20-0.64; p=0.0004).
Conclusions: The presence of liver metastases is associated with lower response rate to immunotherapy-based regimen. Patients with severe liver metastases demonstrated significantly lower odds of response compared to those with no or mild/moderate metastases. Therefore, severe liver metastases may represent a clinically meaningful threshold for worse response and may inform risk stratification and clinical trial eligibility.
利益披露 Disclosure
J. Ahmed,
NCI Employment, However, Dr. Ahmed participated in this work described in the abstract during his employment at The University of Texas MD Anderson Cancer Center.
B. Stephen,
The University of Texas MD Anderson Cancer Center Employment.
E. Kwiatkowski,
UT Health Houston Employment.
M. R. Anderson,
The University of Texas MD Anderson Cancer Center Employment.
M. H. Derbala,
The University of Texas MD Anderson Cancer Center Employment.
I. Salih,
The University of Texas MD Anderson Cancer Center Employment.
L. Castillo,
The University of Texas MD Anderson Cancer Center Employment.
Y. Yang,
The University of Texas MD Anderson Cancer Center Employment.
S. A. Gurses,
The University of Texas MD Anderson Cancer Center Employment.
H. Yan, None.
J. T. Lim,
The University of Texas MD Anderson Cancer Center Employment.
A. R. Klekers,
The University of Texas MD Anderson Cancer Center Employment.
H. Le,
The University of Texas MD Anderson Cancer Center Employment.
L. Kang,
The University of Texas MD Anderson Cancer Center Employment.
M. Xu,
The University of Texas MD Anderson Cancer Center Employment.
H. N. Tan,
The University of Texas MD Anderson Cancer Center Employment.
S. Champiat,
The University of Texas MD Anderson Cancer Center Employment.
Amgen; Astellas; AstraZeneca; Bristol Myers Squibb; Eisai; Genmab; Janssen; Merck KGaA; MSD; Novartis; Roche and Servier Other, Speaking Engagement.
Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bolt Biotherapeutics; Centessa Pharmaceuticals; Cytovation; Eisai; GlaxoSmithKline; Imcheck Therapeutics; Immunocore; Kumquat Biosciences; Marengo; ).
Molecular Partners Ag; MSD; OncoC4; Ose Immunotherapeutics; Owkin; Pheast; Pierre Fabre; Replimune; Roche; Sanofi Aventis; Seagen; Sotio A.S; Transgene; Trutino Biosciences ).
AccessTrial; Alderaan Biotechnology; Amgen; AstraZeneca; Aummune; Avacta; Bayer; Beigene; BioNTech; Celanese; Compugen; Domain Therapeutics; Ellipses Pharma; Genmab; Guardant; Immunicom; Inc.; Other, Advisory Board/Consulting.
Mariana Oncology; Mima Health; Nanobiotix; Nextcure; NetCancer; Oncovita; Pharma Mar; Pierre Fabre; Replimune; Seagen; Takeda; Tatum Bioscience; Tollys; UltraHuman8 Other, Advisory Board/Consulting.
Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; MSD; Ose Immunotherapeutics; Roche; Sotio Travel, Other, and congress.
Avacta Stock.
T. Tang,
The University of Texas MD Anderson Cancer Center Employment.
E. E. Dumbrava,
The University of Texas MD Anderson Cancer Center Employment.
Bayer HealthCare Pharmaceuticals Inc; Immunocore LTD; Amgen; Aileron Therapeutics; Compugen Ltd; Gilead; BOLT Therapeutics; Aprea Therapeutics; Bellicum Pharmaceuticals; PMV Pharma; ).
Triumvira Immunologics; Seagen Inc; Mereo BioPharma 5 Inc; Sanofi; Rain Oncology; Astex Therapeutics; Sotio Biotech; Poseida; Mersana Therapeutics; Genentech; Boehringer Ingelheim; ).
Dragonfly Therapeutics; A2A Pharma; Volastra; AstraZeneca; Modex Therapeutics; Fate Therapeutics; Pfizer; JacobiostraZeneca. ).
BOLT Therapeutics; Mersana Therapeutics; Orum Therapeutics; Summit Therapeutics; PMV Pharma; Fate Therapeutics; Astra Zeneca Other, Advisory Board.
PMV Pharma; Boehringer Ingelheim; BOLT Therapeutics Other, Speaker.
ASCO; AACR; LFSA Association; Rain Oncology; Banner MD Anderson Cancer Center; Triumvira Immunologics; KSMO; Boehringer Ingelheim Travel, Other, Accommodations and Expenses.
S. A. Piha-Paul,
The University of Texas MD Anderson Cancer Center Employment.
Alkermes; Aminex Therapeutics; BioMarin Pharmaceutical; Inc; Boehringer Ingelheim; Chugai Pharmaceutical Co.; Ltd; Cyclacel Pharmaceuticals; Daiichi Sankyo; Day One Biopharmaeuticals; Eli Lilly & Co. ).
ENB Therapeutics; Epigenetix Inc.; Genmab US; Inc.; Gilead Sciences; Inc.; Hengrui Pharmaceuticals; Co.; Ltd.; Immunity Bio; Inc.; Immunome; Inc.; Immunomedics; Inc.; Incyte Corp.; Innovent Biologics ).
Jazz Pharmaceuticals; Jiangsu Simcere Pharmaceuticals; Johnson & Johnson; Loxo Oncology; Inc.; Merck Sharp and Dohme Corp.; Mitsubishi Tanabe Pharma America (MTPA) Inc.; Nectin Therapeutics; Ltd.; ).
Nested Therapeutics; Inc.; Nurix; OncoNano Medicine; Inc; Pieris Pharmaceuticals; Inc.; Pfizer; Phanes Therapeutics; Puma Biotechnology; Inc.; Purinomia Biotech; Inc.; Replimune; Solve Therapeutics; ).
Strand Therapeutics; Inc.; Theradex Oncology; Toragen Therapeutics; Inc.; TransThera Bio; Xencor; Inc; Zielbio; Inc.; ).
NCI/NIH: P30CA016672 – Core Grant (CCSG Shared Resources); CPRIT Grant: Cancer Prevention Research Institute of Texas (CPRIT) Precision Oncology Decision Support Core (RP150535) and Clinical and Tran ).
Mitsubishi Tanabe Pharma America (MTPA) Inc. Other, Consultant.
J. Rodon Ahnert,
The University of Texas MD Anderson Cancer Center Employment.
European Society for Medical Oncology; American Society of Medical Oncology; Dava Oncology; STOP Cancer Travel, Other, non-financial support.
Ellipses Pharma; Lonctura; Amgen; Merus; MonteRosa; Bridgebio; Debio; Bristol Myers Squibb; and BioHybrid Solutions Travel, consulting (including serving on the scientific advisory board).
Vall d'Hebron Institute of Oncology; AstraZeneca; Boxer Capital LLC; Ecor1; Tang Advisors; LLC; Guidepoint Consulting.
Blueprint Medicines; Merck Sharp & Dohme; Hummingbird; AstraZenneca; 280 Bio; Vall d'Hebron Institute of Oncology/Cancer Core Europe; and Bristol Myers Squibb ).
Cancer Core Europe; Pfizer; Kelun-Biotech; Roche Pharmaceuticals; 280 Bio; Bicycle Therapeutics; ForeBio; Ideaya; Amgen; Tango Therapeutics; Bristol Myers Squibb; MonteRosa; Debio; Beigene; ), serving as investigator in clinical trials.
Relay; Novartis; Scorpion Therapeutics; Incyte; Parabilis Pharmaceuticals; Tyra; Nuvectis Pharma; Adcentrix; Vividion; AstraZenneca; Alnylam; Immuneering Corp; Alterome; Exelixis; Ensem; Bridgebio; ), serving as investigator in clinical trials.
Cogent; Biohaven; Insilico Medicines; Ipsen; Eli Lilly; Seed; and Zai Labs. ), serving as investigator in clinical trials.
A. M. Tsimberidou,
The University of Texas MD Anderson Cancer Center Employment.
7 Hills Pharma; LLC; Immatics; OBI Pharma; Tempus; Parker Institute for Cancer Immunotherapy; Agenus; Novocure; Tvardi Therapeutics; Orionis; Tachyon; Vividion Therapeutics; AbbVie Macrogenics; ).
Avaneon; Karus Therapeutics Ltd.; Xadcera Biopharmaceutical Co ).
Clinical and Translational Science Award Grant Grant (CTSA) 1UM1TR0045906; Cancer Prevention Research Institute of Texas (CPRIT DP230062); and Precision Oncology Decision Support Core (CPRIT RP15053 ).
BrYet; NEX-I; OBI Pharma; Integra Connect Consulting or Advisory Role.
WIN Consortium Travel.
T. A. Yap,
The University of Texas MD Anderson Cancer Center Employment, ; where I am Vice President; Head Clinical Development in the Therapeutics Discovery Division; which has a commercial interest in DNA damage response (DDR) and other inhibitors(IACS30380/ ART0380 was licensed to Artios).
Acrivon; Artios; AstraZeneca; Bayer; BeiGene; BioNTech; Blueprint; Bristol Myers Squibb; Boundless Bio; Clovis; Constellation; Cyteir; Eli Lilly; EMD Serono; Forbius; F-Star; GlaxoSmithKline; ).
Genentech; Haihe; Ideaya ImmuneSensor; Insilico Medicine; Ionis; Ipsen; Jounce; Karyopharm; KSQ; Kyowa; Merck; Mirati; Novartis; Pfizer; Ribon Therapeutics; Regeneron; Repare; Rubius; Sanofi; ).
Scholar Rock; Seattle Genetics; Tango; Tesaro; Vivace; and Zenith ).
NCI Cancer Center Support Grant CA016672 to The University of Texas MD Anderson Cancer Center; Department of Defence grants W81XWH2210504_BC211174 and W81XWH-21-1-0282_OC200482; V Foundation Scholar ).
AbbVie; Acrivon; Adagene; Almac; Aduro; Amphista; Artios; Astex; AstraZeneca; Athena; Atrin; Avenzo; Avoro; Axiom; Baptist Health Systems; Bayer; BeiGene; BioCity Pharma; Blueprint; Boxer; Other, Consultant.
Bristol Myers Squibb; C4 Therapeutics; Calithera; Cancer Research UK; Carrick Therapeutics; Circle Pharma; Clovis; Cybrexa; Daiichi Sankyo; Dark Blue Therapeutics; Diffusion; Duke Street Bio; Other, Consultant.
858 Therapeutics; EcoR1 Capital; Ellipses Pharma; EMD Serono; Entos; F-Star; Genesis Therapeutics; Genmab; Glenmark; GLG; Globe Life Sciences; GSK; Guidepoint; Ideaya Biosciences; Idience; Other, Consultant.
Ignyta; I-Mab; ImmuneSensor; Impact Therapeutics; Institut Gustave Roussy; Intellisphere; Jansen; Kyn; MEI pharma; Mereo; Merck; Merit; Monte Rosa Therapeutics; Natera; Nested Therapeutics; Nexys; Other, Consultant.
Nimbus; Novocure; Odyssey; OHSU; OncoSec; Ono Pharma; Onxeo; PanAngium Therapeutics; Pegascy; PER; Pfizer; Piper-Sandler; Pliant Therapeutics; Prolynx; Radiopharma Theranostics; Repare; resTORbio; Other, Consultant.
Roche; Ryvu Therapeutics; SAKK; Sanofi; Schrodinger; Servier; Synnovation; Synthis Therapeutics; Tango; TCG Crossover; TD2; Terremoto Biosciences; Tessellate Bio; Theragnostics; Terns Pharmaceuticals Other, Consultant.
Tolremo; Tome; Thryv Therapeutics; Trevarx Biomedical; Varian; Veeva; Versant; Vibliome; Voronoi Inc; Xinthera; Zai Labs; and ZielBio Other, Consultant.
S. Fu,
The University of Texas MD Anderson Cancer Center Employment.
Abbisko; Antengene; BeiGene; BeyondSpring Pharmaceuticals; Inc.; LLC.; Biotheus Inc; Boehringer Ingelheim; Coherent Biopharma; LLC; Crossignal Therapeutics; Inc.; CUE Biopharma; Inc.; ).
DEKA Biosciences; Eli Lilly & Co.; Exelixis; Fore Biotherapeutics; Greenfire Bio; Inc.; Hookipa Biotech; IMV; Inc.; Innovent Biologics; Co.; Ltd.; Jazz Pharmaceuticlals; K-Group Beta; ).
Lantern Pharma Inc.; Lyvgen Biopharm; Co.; Ltd.; MacroGenics; MediLink Therapeutics; Co. Ltd.; Millennium Pharmaceuticals; Inc.; Nerviano Medical Sciences; NeuPharma; Inc.; NextCure; Inc.; ).
Ningbo NewBay Technology Development Co.; Ltd.; Novartis; NovoCure; Nykode Therapeutics AS.; Parexel International; LLC; PharmaMar USA; Inc.; Pionyr Immunotherapeutics; Inc.; PureTech Health; LLC; ).
Qurgen; Inc.; Shanghai Huaota Biopharmaceutical Co.; Ltd.; Sellas Life Sciences Group; Soricimed Biopharma; Inc.; SQZ Biotechnologies; Sumitomo Dainippon; Taiho Oncology and NCCN; Tigermed Group; LLC ).
TransCode Therapeutics; Inc.; Treadwell Therapeutics; Turnstone Biologics; Tyligand Bioscience; Ltd.; Virogin Biotech; Ltd.; ).
NIH/NCI P30CA016672 – Core Grant (CCSG Shared Resources); ).
CPRIT Grant: Cancer Prevention Research Institute of Texas (CPRIT) Precision Oncology Decision Support Core (RP150535); Clinical and Translational Science Award Grant (CTSA) 1UM1TR0045906 ).
D. S. Hong,
The University of Texas MD Anderson Cancer Center Employment.
280Bio; AbbVie; Aldai-Nortye; Alterome; Amgen; Astelles; Astra-Zeneca; Bayer; BeiGene USA; BridgeBio; Biomea Fusion; Bristol-Myers Squibb; Chong Kun Dang; Deciphera; Eli Lilly; Endeavor; Erasca; ).
Exelixis Inc.; F. Hoffmann-LaRoche; Genentech; Immunogenesis; Incyte Inc.; Inhibrix; KumQuat; Merck; Mirati; NCI-CTEP; Pfizer; Quanta Therapeutics; Revolution Medicines; VM Oncology; ).
American Association of Cancer Research (AACR); American Society of Clinical Oncology (ASCO); Bayer; BeiGene USA Inc.; Genmab; Immunogenesis; Medscape; Mirati Therapeutics Inc.; Pfizer; Travel, Other, Accommodations; Expenses.
Society for the Immunotherapy of Cancer (SITC); Telperian Travel, Other, Accommodations; Expenses.
280 Bio; Acuta Capital Partners LLC; Alpha Insights; Amgen; Bain Capital; Bayer; BluePrint Medicine; BlueStar; Boxer Capital; Breakthrough Bio; Children’s Oncology Group; COR2ed; Cowen Group Inc; Other, Consulting; Speaker; or Advisory Role.
Crossbridge Bio; Ecor1 Capital; Erasca; Gerson Lehrman Group Inc.; Group H; Guidepoint; Immunogenesis; Janssen Pharmaceuticals; Kestrel Therapeutics; Medacorp; Medscape; Orbi Capital; Pfizer; Other, Consulting; Speaker; or Advisory Role.
PharmaResearch; Remedy Inc; Revolution Medicines; Stipple Bio;T-Knife; TouchEd; Travistock Group; Xencor; WebMD Other, Consulting; Speaker; or Advisory Role.
Molecular Match (Advisor); OncoResponse (Founder; Advisor); Telperian (Founder; Advisor); CrossBridge Bio (Advisor) Other, Other ownership interests.
F. Meric-Bernstam,
The University of Texas MD Anderson Cancer Center Employment.
AstraZeneca Pharmaceuticals; Becton Dickinson; Biocartis NV; Calibr (a division of Scripps Research); Daiichi Sankyo; Dava Oncology; Debiopharm; EcoR1 Capital; eFFECTOR Therapeutics; Other, personal fees.
Elevation Oncology; Exelixis; GT Aperion; Incyte; Jazz Pharmaceuticals; LigaChem Biosciences; Menarini Group; ModeX Therapeutics; Inc.; Molecular Templates; Protai Bio; Ribometrix; SystImmune; TEMPUS Other, personal fees.
Vir Biotechnology; Zymeworks. Other, personal fees.
Cybrexa Therapeutics; go Therapeutics; Guardant Health; Harbinger Health; Illumen Therapeutics; Kivu Biosciences; LOXO-Oncology; Mersana Therapeutics; OnCusp Therapeutics; Sanofi Pharmaceuticals; advisory role.
Seagen (formerly Seattle Genetics); Theratechnologies Inc.; Zentalis Pharmaceuticals. advisory role.
AstraZeneca; Daiichi Sankyo Co. Ltd.; Debiopharm International; eFFECTOR Therapeutics; Guardant Health Inc.; Jazz Pharmaceuticals; Zymeworks ).
Dava Oncology Other, Honoraria.
Cholangiocarcinoma Foundation; Dava Oncology; European Organisation for Research and Treatment of Cancer (EORTC); European Society for Medical Oncology (ESMO); Physician Education Resource (PER) Travel, Travel-related support.
P. R. Bhosale,
The University of Texas MD Anderson Cancer Center Employment.
A. Naing,
The University of Texas MD Anderson Cancer Center Employment.
NCI; EMD Serono; MedImmune; Healios Onc. Nutrition; Atterocor/Millendo; Amplimmune; ARMO BioSciences; Karyopharm Therapeutics; Incyte; Novartis; Regeneron; Merck; Bristol-Myers Squibb; Pfizer; ).
CytomX Therapeutics; Neon Therapeutics; Calithera Biosciences; TopAlliance Biosciences; Eli Lilly; Kymab; PsiOxus; Arcus Biosciences; NeoImmuneTech; Immune-Onc Therapeutics; Surface Oncology; ).
Monopteros Therapeutics; BioNTech SE; Seven & Eight Biopharma; and SOTIO Biotech AG; GV 20 Therapeutics ).
CTI; Deka Biosciences; Janssen Biotech; NGM Bio; PsiOxus Therapeutics; Immune-Onc Therapeutics; STCube Pharmaceuticals; OncoSec KEYNOTE-695; Genome & Company; CytomX Therapeutics; Nouscom; Other, advisory board/Consulting fees.
Merck Sharp & Dohme Corp; Servier; Lynx Health; AbbVie Mural Oncology Other, advisory board/Consulting fees.
ARMO BioSciences; NeoImmuneTech; NGM Biopharmaceuticals Travel, Other, and accommodation expense.
AKH Inc; The Lynx Group; Society for Immunotherapy of Cancer (SITC); Korean Society of Medical Oncology (KSMO); Scripps Cancer Care Symposium; ASCO Direct Oncology Highlights; Other, Honoraria for speaking engagements.
European Society for Medical Oncology (ESMO); CME Outfitters Other, Honoraria for speaking engagements.
R01-1R01CA279749-01A1 (PI/PD); 1R01CA269622 (Co-I); P30CA016672 – Core Grant (CCSG Shared Resources) ).
KN Foundation USA Founder.